170 related articles for article (PubMed ID: 2408170)
1. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
Catalona WJ; Ratliff TL
Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
[No Abstract] [Full Text] [Related]
2. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
3. [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
Ackermann D; Schnyder M; Bandelier D; Studer UE
J Urol (Paris); 1986; 92(1):33-8. PubMed ID: 3722851
[TBL] [Abstract][Full Text] [Related]
4. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
Aso Y; Akaza H; Kameyama S; Niijima T
Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
[No Abstract] [Full Text] [Related]
6. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
7. [Intravesical Calmette-Guérin bacillus therapy of bladder tumors].
Uchida T; Muruyama M; Igarashi M; Kobayashi K; Mashimo S; Ishibashi A; Koshiba K; Shibuya M
Nihon Hinyokika Gakkai Zasshi; 1987 Dec; 78(12):2087-97. PubMed ID: 3451983
[No Abstract] [Full Text] [Related]
8. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
9. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with bacillus Calmette-Guerin in patients with superficial bladder cancer.
Swibold LK
Urol Nurs; 1999 Mar; 19(1):38-41. PubMed ID: 10373991
[TBL] [Abstract][Full Text] [Related]
11. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
12. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
Sosnowski JT
Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
[No Abstract] [Full Text] [Related]
13. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
14. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
[TBL] [Abstract][Full Text] [Related]
15. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
17. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
Okuno H; Shirahase T; Kihara Y; Arai Y
Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
[TBL] [Abstract][Full Text] [Related]
18. Superficial bladder disease: case studies and therapeutic advances.
Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
[No Abstract] [Full Text] [Related]
19. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.
Vegt PD; Witjes JA; Witjes WP; Doesburg WH; Debruyne FM; van der Meijden AP
J Urol; 1995 Mar; 153(3 Pt 2):929-33. PubMed ID: 7853577
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress of red blood cells during Bacillus Calmette-Guerin intravesical instillations.
Mitropoulos D; Deliconstantinos G; Zervas A; Giannopoulos A; Kyriakou G; Dimopoulos C
In Vivo; 2000; 14(6):721-4. PubMed ID: 11204488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
